Original Research Article

CHILDHOOD URINARY TRACT INFECTION: CLINICAL SIGNS, BACTERIAL CAUSES AND ANTIBIOTIC SUSCEPTIBILITY

ABSTRACT

Background and objective: Urinary tract infections (UTIs) are the neglected infection in children from the side of study its clinical symptoms, causative organisms and their antibiotic sensitivity. This investigation seeks to determine clinical symptoms frequency, prevalence rate, bacterial features, and antibiotic sensitivity of bacterial urinary tract infection in children attending private children's health center in Sana'a city.

Methods: In a prospective study undertaken over a 24-month period, 1925 samples from children patients suspected of having a UTI were analyzed, of which 175 were culture-positive. Clinical and demographic data were collected. Isolated bacteria were identified by standard tests, and antibiotic susceptibility was determined by disk diffusion method.

Results: Fever was the most frequent symptom occurred (88%) while other UTI symptoms were less frequent than that reported in adult patients for UTI. *Escherichia coli* was the most common etiological agent (89.7%), followed *Staphylococcus aureus* (3.4%), *Klebsiella* spp (2.9%), *Proteus* spp (2.3%), and *beta haemolytic streptococci* (1.7%). Results of antimicrobial resistant for *E. coli*, as the most prevalent cause of UTI, to commonly used antibiotics are ranged from less than 3% for Levoflxacin, Gentamicin, Amikacin and Cefoxitin to more than 75% for Tetracycline, Nalidixic Acid, Doxycycline, Co-Trimoxazol and Amoxcillin .

Conclusions: The results show the most common symptom of UTI are fever and lack of more obvious symptoms of UTI in adult patients. The antimicrobial resistance patterns of the causes of UTI are highly variable and continuous surveillance of trends in resistance patterns of uropathogens among children is important.

Key words: Children, UTI, UTI symptoms, bacterial causes, antibiotic resistant , Sana'a, Yemen

INTRODUCTION

A urinary tract infection (UTI) is an infection that affects part of the urinary tract [1]. As the lower urinary tract infection, which is known as cystitis and when it affects the upper urinary tract, it is known as pyelonephritis [2]. As for the symptoms resulting from lower urinary tract infection, they include pain during urination, frequent urination, and the feeling of needing to urinate despite the presence of an empty bladder [2,3]. The symptoms of kidney infection include fever and flank pain and rarely, blood appears in the urine. In the elderly and the young, the symptoms are vague or non-specific[1,4]. In young children, researchers have found that the only symptom of UTI is fever [5]. Therefore, because there are no more obvious symptoms, when the fever appears in females under the age of two or in males less than a year old, it is recommended to do a bacterial culture of the child's urine. Also, one of the symptoms in children is that children feed poorly, vomit, sleep more than normal, or may show signs of jaundice. However, in older children, new onset of enuresis (loss of bladder control) may occur. Researchers have found that about 1 in 400 infants 1 to 3 months of age with a UTI also develops bacterial meningitis by the same bacterial isolates of the urine infection [5,6].

Overall, urinary tract infections (UTIs) are one of the most common infectious diseases, and it is likely that approximately 10% of people will develop a UTI during their lifetime [7,8]. It is known that UTIs are the most common after upper respiratory tract infections in humans[9]. This infection may be clinically symptomatic or asymptomatic, and upper or lower UTI infection may lead to serious consequences if left untreated[10]. Many different microorganisms can cause UTIs, including fungi and viruses, but bacteria are the main causative organisms and cause more than 95% of UTI cases [11]. Since bacteria are the important cause of UTI, *Escherichia coli* is the most common UTI-causing organism and is solely responsible for more than 80% of these infections. Accurate and prompt diagnosis of UTI is important in shortening the course of the disease and preventing transmission of infection to the upper urinary tract, which may lead to kidney failure[12, 13].

The choice of antibiotics and the inappropriate dose leads to treatment failure and an increase in antibiotic resistance; and with recurrent UTIs, in particular, it may lead to permanent injuries such as renal parenchymal scarring, impaired renal function, high blood pressure, and chronic kidney disease[14]. In addition, frequent antibiotic use or urinary tract abnormalities are risk factors for developing resistance and

although there are regional differences, resistance to antibiotics used in empirical therapy is gradually increasing worldwide and in our country[15-17, 18-32]. It should be known and considered that the most frequently grown microorganisms may be resistant to antibiotics when choosing experimental antibiotic therapy. Treatment for UTIs often begins with an experiment. Treatment is based on specific information from the antimicrobial resistance pattern of urinary pathogens. Nevertheless, due to the developing and persistent phenomenon of antibiotic resistance, regular monitoring of resistance patterns is essential to improve the guidelines for empirical antibiotic therapy [30-32].

The aim of this study was to determine the frequency of clinical symptoms, prevalence, bacterial features, and antibiotic sensitivity of UTIs in children attending the private pediatric health center in Sana'a city, Yemen.

Material and Methods

Study design

This was a retrospective descriptive study. Clinical and microbiological data for the 2019-2020 biennium were obtained from the Pediatric Department of Sam Medical Center (Private Childhood Hospital) in Sana'a City, Yemen. Clinical and demographic data were collected in a pre-designed questionnaire. Cultivation and identification were performed at the Microbiology Department of the National Center of Public Laboratories (NCPHL), Sana'a City. Urine samples were collected from 1925 outpatient children with suspected UTI, who had not received antimicrobials within the past two months, and referred to theNCPHL for Urine Culture. There were 1459 (75.8%) samples of female patients and 466 (24.2%) of male patients. The patient's age ranged from 7 months to 13 years (mean age 7.7 ± 5.2 years). Children older than 3 years were sampled with clean urine midstream, and children younger than 3 years old were sampled using sterile urine bags.

Isolation and identification of organisms

Urine samples were examined and cultured within an hour of sampling. All samples were inoculated on blood agar plus MacConkey agar and incubated at 37 °C for 24 h, and for 48 h in negative cases. The sample was considered positive for urinary tract infection if single organism was cultured at a concentration of 10^5 cfu/ml, or when single organism was cultured at a concentration of 10^4 cfu/ml and 5 leukocytes per high-power field were observed on urine microscopy. The bacteria were identified on the basis of standard culture and biochemical characteristics of the isolates. Gram-negative bacteria were identified by standard biochemical tests [11,12]. Gram-positive bacteria were identified by the corresponding laboratory tests: catalase, coagulase, CAMP test (for *Streptococcus agalactiae*), and esculin agar (for *enterococci*) [33].

Susceptibility testing

The isolates were tested for antimicrobial susceptibility by disc diffusion method consistent with the approvals of the National Committee for Clinical Laboratory Standards (NCCLS), employing Muller-Hinton medium[12]. The antimicrobial agents tested were: amikacin, amoxicillin, ampicillin, ampicillin-sulbactam, augmentin, azithromycin, aztronam, cefaclor, cefadroxam, cefepime, cefixime, cefotaxime, cefoxitin, ceftazidime, ceftriaxin, erythromycin, gentamicin, fosfomycin, levofloxacin, levofloxacin, moxifloxacin, nalidixic acid, nitrofuranthion, piperacillin/tazobactam, tetracycline and vancomycin (BD-BBL-TM-Sensi-Disc-TM).

Statistical analysis

Discrete variables were expressed as percentages and proportions were compared using the Chi-square test[34].

RESULTS

Over a 24-month period, 1925 urine samples from children outpatients were analyzed, of which 175 (9.1%) had significant bacteriuria. The rate of positive culture was 8.4% (124/1459) for female subjects and 10.9% (51/466) for male subjects (Table 1). Table 2 shows the frequency of clinical signs of UTI among children. The usual clinical symptoms of upper and lower UTIs in the current study were significantly lower than those reported in adults, with the rate of pain above the pubic bone, lower back pain, flank pain, urine appearing bloody, and visible pus in urine <50 %. Whereas, the most important symptom was fever, which occurred in 88% of the children completely, followed by enuresis as a new onset (73.1%). Also, the symptom of poorly nourished children occurred at 57.1% in children under the age of one year, vomiting was recorded in 14.3%, and the presentation of sleeping more than usual in 58.9% and burning during urination was recorded in 56%. Gram-negative bacilli were responsible for 94.9% of cases followed by Gram-positive bacteria responsible for 5.1% of cases. Analysis of the results according to patient gender indicated that although *E. coli* is the predominant pathogen isolated from both sexes, it

occurs significantly in female children (91.8% for females compared to 84.9% for males; P<0.05), whereas The prevalence of urinary tract infection due to *Klebsiella* species and *Proteus* species was 2.9% and 2.5%, respectively. The prevalence of UTI caused by *Staphylococcus aureus* in males (5.7%) was higher than in females (2.5%) (Table 3). Table 4 shows the pattern of antibiotic resistance of microorganisms in children with UTI. The resistance rates of isolates to a group of antibiotics, including penicillins, cephalosporins, quinolones, aminoglycosides, and trimethoprim-sulfamethoxazole, that are routinely used to treat UTIs, are shown in Table 4. *Escherichia coli* as the predominant cause of UTI, showed higher the proportion of resistance to amoxillin (91.5%), nalidixic acid (88.5%) and tetracycline (88.5%) while the least resistant to *E. coli* were to levofloxacin (1.9%), amikacin (2.5%), cefoxin (2.5%). %), gentamicin (2.5%), moxifloxacin (3.2%), lfomfloxacin (3.8%), Ertapenem (5.1%), and aztronam (6.4%). *Klebsiella* spp as the second predominant UTI pathogen showed a similar resistance pattern and was 100% resistant to amoxicillin, ampicillin and augmentin, while 80% was resistant to azithromycin, cefaclor, cefadroxam, nalidixic acid, tetracycline and doxycycline. *Proteus* species also showed a high rate of antibiotic resistance to many of the antibiotics tested (Table 4). *Staphylococcus aureus* was 100% resistant to amoxicillin, ampicillin and azithromycin, while all isolates of S.aureus were sensitive to vancomycin.

DISCUSSION

Urinary tract infection is a common disease in children, especially females, where in the current study 78.86% of cases were females, while only 21.24% of male cases, and this is similar to what was mentioned in the previous literature [35-37]. Infection generally occurs with colonization of the lower urinary tract by microorganisms, most of which are Gram-negative. The infection may extend from the bladder to the kidneys, depending on the characteristics of the pathogen. It is known that infection is rarely transmitted by the hematogenous route and may occur as a result of transmission of the agent to the urinary tract through the blood during sepsis. Vesicoureteral reflux, voiding dysfunctions, neurogenic bladder, urinary incontinence, constipation, bladder neck obstruction, and the presence of a catheter are predisposing factors for UTI[35]. Another factor is familial and genetic predisposition[36].

Clinical outcomes in pediatric UTI vary according to age, location in the urinary tract, and severity of infection [37]. In the neonatal and pediatric period, the signs are mostly nonspecific[38]. Diagnosis is based mostly on the patient's symptoms and results of the physical examination and urinalysis, and treatment generally begins empirically[39]. However, increasing antibiotic resistance nowadays leads to treatment failure and an increase in acute cases. It is now known that antibiotic resistance has become an important problem for hospital infections, and for community-acquired infections[40]. Therefore, it is recommended that the resistance rate does not exceed 10-20% to start experimental treatment in any region of the world[41]. For that reason, the American Infectious Diseases Society give emphasis to that regional pathogenic agents and antibiotic sensitivities in UTIs should be known[42].

Microbial infection of the urinary tract is one of the most common diseases worldwide. In this study, of 1925 children clinically diagnosed with a UTI, samples were taken and only 9.1% had a UTI while the others gave negative culture results. This is probably because UTI symptoms are not a reliable indicator of infection and also that children under 5 years of age have nonspecific UTI symptoms. This is similar to that reported by Farajnias, *et al.* in Iran in their study, of the 5,136 patients from whom urine samples were taken, only 13.2% had a UTI[1]. In the current investigation, most urine samples were collected from pediatric patients who did not have a symptomatic group of UTI, and most of the subjects were referred by general practitioners and specialist physicians. These results indicate that urine culture is essential for the definitive diagnosis of urinary tract disease, and that empirical treatment should only be performed in the absence of urine culture examination [7]. The results of the current study show a higher number of females (124 females versus 51 males) (Table 1). This may be that males are less likely to develop UTIs due to the length of their urethra[7].

Although the prevalence of UTIs causative agents in different parts of the world is somewhat similar, the patterns of antimicrobial resistance reported from different regions are significantly different and antimicrobial resistance is increasing in the world. The results of our study show that among the heterogeneous causative organisms for UTI, *Enterobacteriaceae* are the dominant pathogens, followed by Gram-positive cocci. These results are consistent with reports published in Yemen previously and from other countries around the world[30-32, 37-39]. In UTI, the causative agent is generally Gram-negative bacteria. The main pathogen is *E. coli*, *Klebsiella*, *Enterobacter* and *Proteus spp*. It has been reported at lower rates[37-39]. Consistent with previous studies, we found that the most common causative agent was *Escherichia coli*, and the female sex was dominant in our study [37-39].

The highest resistances were found to amoxicillin (91.5%), ampicillin (90.7%), doxacillin (95.5%), trimethoprim-sulfamethoxazole (75.2%), and nalidixic acid (88.5%), while the least resistant to *E. coli* were to levofloxacin (1.9%), amikacin (2.5%), cefoxin (2.5%). %), gentamicin (2.5%), moxifloxacin (3.2%), lfomfloxacin (3.8%), Ertapenem (5.1%), aztronam (6.4%); these results are mainly consistent with other studies conducted previously in Yemen[18-32] and around the world[7-11]. The present study, as with previous studies, shows that *Escherichia coli* is the predominant etiology of UTI[32,43,44] and also reveals a very high rate of bacterial resistance to antibiotics. This was particularly the case for the *Klebbsilla* species and *Proteus* species that were completely resistant to ampicillin, cephalexin, nitrofurantoin, nalidixic acid and trimethoprim-sulfamethoxazole; this resistance is higher than that of other reports[32, 44, 45]. Over the past decade there has been a significant increase in the resistance of urinary pathogens to antibiotics. Resistance rates are increasing among strains of *Staphylococcus aureus*, and a significant portion of this species has become resistant to *beta-lactamase*-resistant penicillin[46]. For such resistant species, vancomycin is the effective drug choice. Vancomycin resistance has been reported among *Enterococci*[47] , but this resistance has also begun to develop among *Staphylococci*. In this study we focused on vancomycin resistance and fortunately no vancomycin-resistant strains were observed, but 100% of cases were resistant to ampicillin, aztreonam, and azithromycin. The regional variations of resistance to antibiotics may be explained in part by different local antibiotic practices[48]. The influence of excessive and/or inappropriate antibiotic use on the development of antibiotic-resistant strains, particularly broad-spectrum agents prescribed empirically, has been demonstrated. Reducing the number of prescriptions of a particular antibiotic can lead to a decrease in resistance rates. Transmission of resistant isolates between people and/or by consumption of foods originated from animals that have received antibiotics and greater mobility of individuals worldwide has also contributed to the expansion of antibiotic resistance. Regional differences in antibiotic resistance may be partially explained by different local antibiotic practices[48]. The outcome of unnecessary and/or improper use of antibiotics on the expansion of antibiotic-resistant strains, especially of broad-spectrum agents described experimentally, has been demonstrated. Reducing the number of prescriptions for a particular antibiotic can lead to lower rates of resistance. Transmission of resistant isolates between people and/or by consumption of foods originating from animals that received antibiotics and greater movement of individuals around the world has also contributed to the expansion of antibiotic resistance[48].

CONCLUSION

In conclusion, since the antibiotic susceptibility pattern of bacteria varies over time and in different geographic regions, antibiotic treatment of infection should be based on local experience of susceptibility and resistance patterns or culture and antibiotic susceptibility testing. In this study, it was found that the Augmentin and aztreonam two most suitable oral antibiotics, amikacin and third generation cephalosporins were the most suitable parenteral antibiotics, for the empirical treatment of urinary tract infection. Also, *Escherichia coli* was the most common causative agent of childhood UTIs.

CONFLICT OF INTEREST

"No conflict of interest associated with this work".

AUTHOR'S CONTRIBUTION

The first author presented the data and the first, and the rest authors analyzed the data and wrote, revised and edited the paper.

REFERENCES

1-Farajnia S, Alikhani MY, Ghotaslou R, Naghili B, Nakhlband A. Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. Int J Infect Dis. 2009 Mar;13(2):140-4. doi: 10.1016/j.ijid.2008.04.014. Epub 2008 Aug 13. PMID: 18703368.

2- *Lane, DR; Takhar, SS. "Diagnosis and management of urinary tract infection and pyelonephritis". Emergency Medicine Clinics of North America 2009; 29 (3): 539–52.* doi:10.1016/j.emc.2011.04.001. PMID 21782073.

3-Salvatore S, Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, Torella M. *"Urinary tract infections in women". European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2011; *156 (2):131-6.* doi:10.1016/j.ejogrb.2011.01.028. PMID 21349630.

4- *Woodford, HJ; George, J.* "Diagnosis and management of urinary infections in older people". Clinical Medicine 2011; *11 (1): 80–3.* doi:10.7861/clinmedicine.11-1-80. PMC 5873814. PMID 21404794.

5- *Bhat RG, Katy TA, Place FC. "Pediatric urinary tract infections". Emergency Medicine Clinics of North America 2011; 29 (3): 637–53.* doi:10.1016/j.emc.2011.04.004. PMID 21782079.

6- *Nugent, J; Childers, M; Singh-Miller, N;* Howard, R; Allard, R; Eberly, M. *"Risk of Meningitis in Infants Aged 29 to 90 Days with Urinary Tract Infection: A Systematic Review and Meta-Analysis". The Journal of Pediatrics 2019; 212: 102–110.e5.* doi:10.1016/j.jpeds. 2019.04.053. PMID 31230888.
7- Hoberman A, Wald ER. Urinary tract infections in young febrile children. Pediatr Infect Dis J. 1997 Jan;16(1):11-7. doi: 10.1097/00006454-199701000-00004. PMID: 9002094.
8- Delanghe JR, Kouri TT, Huber AR, Hannemann-Pohl K, Guder WG, Lun A, Sinha P, Stamminger G, Beier L. The role of automated urine particle flow cytometry in clinical practice. Clin Chim Acta. 2000 Nov;301(1-2):1-18. doi: 10.1016/s0009-8981(00)00342-9. PMID: 11020458.
9- Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother. 2001 Jun;47(6):773-80. doi: 10.1093/jac/47.6.773. PMID: 11389109.
10- Pezzlo M. Detection of urinary tract infections by rapid methods. Clin Microbiol Rev. 1988 Jul;1(3):268-80. doi: 10.1128/CMR.1.3.268. PMID: 3058296; PMCID: PMC358050.
11- Bonadio M, Meini M, Spitaleri P, Gigli C. Current microbiological and clinical aspects of urinary tract infections. Eur Urol. 2001 Oct;40(4):439-44; discussion 445. doi: 10.1159/000049813. PMID: 11713400.
12- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disc susceptibility tests. 7th ed. Wayne, Pennsylvania, USA: NCCLS; 2000. M2—A7.
13-Kandur Y, Küpeli S. Vezikoüretral reflüve idrar yolu enfeksiyonu. Klinik Pediatri. 2003;2:69–73. [Google Scholar]
14- Elder JS. Urinary tract infection and vesico ureteral reflux. In: Behrman RE, Kleigman RM, Jenson HB, editors. Nelson Textbook of Pediatrics. 19th edition. Philadelphia: Saunders; 2011. pp. 1829–34. [Google Scholar]
15- Peña C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant *Escherichia coli* in bloodstream infections. Antimicrob Agents Chemother. 1995 Feb;39(2):520-4. doi: 10.1128/AAC.39.2.520. PMID: 7726525; PMCID: PMC162571.
16- Ladhani S, Gransden W. Increasing antibiotic resistance among urinary tract isolates. Arch Dis Child. 2003;88:444–5. [PMC free article] [PubMed] [Google Scholar]
17- Prais D, Straussberg R, Avitzur Y, Nussinovitch M, Harel L, Amir J. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child. 2003;88:215–8. [PMC free article] [PubMed] [Google Scholar]
18-Abbas AM, Al-Kibsi TAM, Al-Akwa AAY, AL-Haddad KA, Al-Shamahy HA, Al-labani MA. Characterization and antibiotic sensitivity of bacteria in orofacial abscesses of odontogenic origin. Universal J Pharm Res 2020; 5(6):36-42. https://doi.org/10.22270/ujpr.v5i6.510
19-Al Hamzi MA, Al-Shamahy HA, Al jorany AA, Al Sharani AA. Phototoxic Effect of Visible Blue Light on *Porphyromonas Gingivalis* and *Aggregatibacter Actinomycetemcomitans*. On J Dent & Oral Health. 2(3): 2019. OJDOH.MS.ID.000540.
20-Al-Akwa, A. A. Y., A. Q. M. Q. Zabara, H. A. Al-Shamahy, M. A. Al-labani, K. M. Al-Ghaffari, A. M. Al-Mortada, A. M. Al-Haddad, and A. A. Al-Sharani. "Prevalence of *staphylococcus aureus* in dental infections and the occurrence of MRSA in isolates". Universal Journal of Pharmaceutical Research 2020; 5(2):1-6. doi:https://doi.org/10.22270/ujpr.v5i2.384.
21-Al-Eryani SA, Alshamahi EYA, Al-Shamahy HA, Alfalahi GHA, Al-Rafiq AA. Bacterial conjunctivitis of adults: causes and ophthalmic antibiotic resistance patterns for the common bacterial isolates. Universal Journal of Pharmaceutical Research 2021; 6(1):25-28. DOI: https://doi.org/10.22270/ujpr.v6i1.535
22-AL-Haddad KA, Ali Al-Najhi MM, Al-Akwa AAY, Al-Shamahy HA, Al-Sharani AA, Al-labani MA (2021) Antimicrobial Susceptibility of *Aggregatibacter Actinomycetemcomitans* Isolated from Localized Aggressive Periodontitis (Lap) Cases. J Dent Ora Heal Ad Re: JDOHAR:103.
23-Al-Haifi, A. Y., A. S. M. Al Makdad, M. K. Salah, H. A. Al-Shamahy, and W. A. A. Al Shehari. "Epidemiology, bacterial profile, and antibiotic sensitivity of lower respiratory tract infections in Sana'a and Dhamar city, Yemen". Universal Journal of Pharmaceutical Research 2020, 5(2):1-6. doi:https://doi.org/10.22270/ujpr.v5i2.386.
24-Alhasani AH, Ishag RA, Yahya Al-Akwa AAY, Al Shamahy HA, Al-labani MA. Association between the *Streptococcus mutans* biofilm formation and dental caries experience and antibiotics resistance in adult females. Universal Journal of Pharmaceutical Research 2020; 5(6):1-3. DOI: https://doi.org/10.22270/ujpr.v5i5.478
25-Al-Hrazi, R. M. A., H. A. Al-Shamahy, and B. M. Jaadan. "Determination of rifampicin mono-resistance *Mycobacterium tuberculosis* in the National tuberculosis control programme in Sana'a city-

Yemen: a significant phenomenon in war region with high prevalence tubercloisis". Universal Journal of Pharmaceutical Research 2019; 4(3):1-9. doi:https://doi.org/10.22270/ujpr.v4i3.266.
26-Al-Safani AA, Al-Shamahy HA, and Al-Moyed KA. "Prevalence, antimicrobial susceptibility pattern and risk factors of *MRSA* isolated from clinical specimens among military patients at 48 medical compound in Sana'a city-Yemen". Universal Journal of Pharmaceutical Research2018; 3(3):40-44. doi:https://doi.org/10.22270/ujpr.v3i3.165.
27-AL-Magrami, R. T. F., and H. A. Al-Shamahy. "*Pseudomonas aeruginosa* skin-nasopharyngeal colonization in the in-patients: prevalence, risk factors and antibiotic resistance in tertiary hospitals in Sana'a city -Yemen". Universal Journal of Pharmaceutical Research 2019; 3(6):1-9. doi:https://doi.org/10.22270/ujpr.v3i6.219.
28-Alshamahi EYA, Al-Shamahy HA, Musawa YA. Bacterial causes and antimicrobial sensitivity pattern of external ocular infections in selected ophthalmology clinics in Sana'a city. Universal Journal of Pharmaceutical Research 2020; 5(3):12-16. DOI: https://doi.org/10.22270/ujpr.v5i3.329
29-Al-Shami IZ, Al-Hamzi MA, Al-Shamahy HA, *et al*. Efficacy of some antibiotics against *Streptococcus mutans* associated with tooth decay in children and their mothers. On J Dent & Oral Health 2019;2(1): 1-6. OJDOH.MS.ID.000530. https://doi.org/10.33552/OJDOH.2019.02.000530
30-Alyahawi, A., A. Alkaf, and T. Alnosary. "Current trend of resistant for the commonly prescribed new fluoroquinolones among hospitalised patients in Sana'a, Yemen". Universal Journal of Pharmaceutical Research, 2018; 3(5):1-6. doi:https://doi.org/10.22270/ujpr.v3i5.197.
31-Alyahawi, A., A. Alkaf, R. Alnamer, and T. Alnosary. "Study of resistance for recently marketed carbapenem drug among hospitalised patients in Sana'a, Yemen". Universal Journal of Pharmaceutical Research, 2018; 3(5): 1-6. doi:https://doi.org/10.22270/ujpr.v3i5.203.
32-Saleh AAM, Al-Shamahy HA, Al-Hrazi RM, Jaadan BM, AL-Magrami RTF, and Al-Sharani AA. "Biofilm formation and antibiotic susceptibility of uropathogens in patients with catheter associated urinary tract infections in Ibb city -Yemen". Universal Journal of Pharmaceutical Research 2020; 4(6):1-6. doi:https://doi.org/10.22270/ujpr.v4i6.329.
33- Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FD, Howard AJ. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8. BMJ. 1999;319(7219):1239-1240. doi:10.1136/bmj.319.7219.1239
34- Hulley S, Cummings S, Browner W. Designing clinical research. 2nd ed. Philadelphia, USA: Lippincott, Williams & Wilkins; 2001.
35-Wald ER. Cystitis and pyelonephritis. In: Feigin RD, Cherry JD, Demler-Harrison GJ, editors. Textbook of pediatric infectious diseases. 6th edition. Philadelphia: Saunders; 2009. pp. 554–69. [Google Scholar]
36- Zaffanello M, Malerba G, Cataldi L, Antoniazzi F, Franchini M, Monti E, Fanos V. Genetic risk for recurrent urinary tract infections in humans: a systematic review. J Biomed Biotechnol. 2010;2010:321082. doi: 10.1155/2010/321082. Epub 2010 Mar 30. PMID: 20379347; PMCID: PMC2847765.
37- Jantausch B, Kher K. Urinary tract infection. In: Kher KK, Schnaper HW, Makker SP, editors. Clinical Pediatric Nephrology. 2nd edition. London: Informa Healthcare; 2006. pp. 553–73. [Google Scholar]
38- Samancı S, Çelik M, Köşker M. Antibiotic resistance in childhood urinary tract infections: A single-center experience. Turk Pediatri Ars. 2020;55(4):386-392. Published 2020 Dec 16. doi:10.14744/TurkPediatriArs.2020.22309
39- Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections. Int J Antimicrob Agents. 1999 May;11(3-4):247-51; discussion 261-4. doi: 10.1016/s0924-8579(99)00024-2. PMID: 10394978.
40-Ansbach RK, Dybus K, Bergeson R. Uncomplicated E. coli urinary tract infection in college women: a follow-up study of *E. coli* sensitivities to commonly prescribed antibiotics. J Am Coll Health. 2005 Sep-Oct;54(2):81-4; discussion 85-6. doi: 10.3200/JACH.54.2.81-84. PMID: 16255319.
41- Rahn DD. Urinary tract infections: contemporary management. Urol Nurs. 2008 Oct;28(5):333-41; quiz 342. PMID: 18980099.
42- Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. Antibiotic resistance of *Escherichia coli* from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect. 2005 Mar;11(3):199-203. doi: 10.1111/j.1469-0691.2004.01057.x. PMID: 15715717.
43- Sharifian M, Karimi A, Tabatabaei SR, Anvaripour N. Microbial sensitivity pattern in urinary tract infections in children: a single center experience of 1,177 urine cultures. Jpn J Infect Dis. 2006 Dec;59(6):380-2. PMID: 17186957.

44- Levtchenko E, Lahy C, Levy J, Ham H, Piepsz A. Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatr Nephrol. 2001 Nov;16(11):878-84. doi: 10.1007/s004670100690. PMID: 11685593.
45- Kapoor H, Aggarwal P. Resistance to quinolones in pathogens causing urinary tract infections. J Commun Dis. 1997 Sep;29(3):263-7. PMID: 9465532.
46- van den Bogaard AE, London N, Driessen C, Stobberingh EE. Antibiotic resistance of faecal *Escherichia coli* in poultry, poultry farmers and poultry slaughterers. J Antimicrob Chemother. 2001 Jun;47(6):763-71. doi: 10.1093/jac/47.6.763. PMID: 11389108.
47Heidari H, Hasanpour S, Ebrahim-Saraie HS, Motamedifar M. High Incidence of Virulence Factors Among Clinical *Enterococcus faecalis* Isolates in Southwestern Iran. Infect Chemother. 2017;49(1):51-56. doi:10.3947/ic.2017.49.1.51
48- Critchley IA, Cotroneo N, Pucci MJ, Mendes R (2019) The burden of antimicrobial resistance among urinary tract isolates of *Escherichia coli* in the United States in 2017. PLoS ONE 14(12): e0220265. https://doi.org/10.1371/journal.pone.0220265

Table 1: The age and sex distribution of children suffering from UTI Sana'a Yemen

Characters	**Number**	**Percentage**	
Sex			
Male	51	29.14	Mean ±SD age =7.5±4.3 year
Female	124	70.86	Mean ±SD age =7.89±5.3 year
Total	**175**	**100**	Mean ±SD age =7.7±5.2 year
Age groups			
Less than 1 year	7	4	
1-5 years	48	27.4	
6-10 years	106	60.6	
More than 10 years	14	8.0	
Total male investigated	**51/466**	**10.9**	
Total female investigated	**124/1459**	**8.4%**	
Total investigated	**175/1925**	**9.1%**	
Max	13 years		
Min	7 months		

Table 2: The frequency of clinical signs of UTI among children in Sana'a Yemen

Signs and symptoms	Number	percentage
Burning while urinating	98	56
Pain above the pubic bone	89	50.9
Lower back pain	72	41.1
Loin pain	79	45.1
Fever	154	88
Urine looks bloody	72	41.1
Visible pus in urine	61	34.9
Babies are feeding poorly (n=7)	4	57.1
Vomiting	25	14.3
Sleep more	103	58.9
Urinary incontinence a new beginning	128	73.1

Table 3: The bacterial causes of children UTI according to sex

Microorganisms	Male		Female		Total	
	No	%	No	%	No	%
Escherichia coli	45	84.9	112	91.8	157	89.7
Klebsiella spp.	2	3.8	3	2.5	5	2.9
Proteus spp.	1	1.9	3	2.5	4	2.3
Total gram negative	48	90.6	118	96.7	166	94.9
Staphylococcus aureus	3	5.7	3	2.5	6	3.4
Beta haemolytic streptococci	2	3.8	1	0.8	3	1.7
Total Gram positive *cocci*	5	9.4	4	3.3	9	5.1
Total	53	29.7	122	70.3	175	100

Table 4: The microorganisms' antibiotic resistances pattern of children UTI

Antibiotics	***E.coli* n=157(%)**	***Klebsiella* spp n=5 (%)**	***Proteus* n=4(%)**	***S.aureus* n=6(%)**	***Beta Gm+ streptococci* n=3(%)**
Amikacin	2.5	0	25	0	0
Amoxcillin	91.5	100	100	100	100
Ampicillin	33.3	100	75	100	66.7
Ampicillin -sulbactam	19.2	20	50	16.7	33.3
Augmentin	8.3	100	75	16.7	33.3
Azithromycin	14	80	75	100	100
Aztreonam	6.4	20	50	0	0
Cefaclor	53.5	80	75	50	66.7
cefadroxam	54.8	80	75	50	66.7
Cefepime	15.3	40	25	0	0
Cefixime	44.6	60	75	0	0
Cefotaxime	7	40	50	0	0
Cefoxitin	2.5	40	50	0	0
Ceftazidime	15.9	40	50	0	0
Ceftriaxone	15.9	40	50	16.7	33.3
Cefuroxime	6.4	20	50	16.7	33.3
Ciprofloxacin	31.8	40	25	16.7	33.3
Clarithromycin	11.5	20	25	0	0
Clindamycin	11.5	20	25	16.7	33.3
Co-Trimoxazol	75.2	100	100	83.3	66.7
Doxycycline	95.5	100	100	16.7	33.3
Ertapenem	5.1	20	25	0	0
Erythromycin	-	-	-	50	66.7
Gentamicin	2.5	20	25	0	0
Fosfomycin	6.4	20	25	0	0
Levoflxacin	1.9	20	25	16.7	33.3
Lfomfloxacin	3.8	20	25	0	0
Moxifloxacin	3.2	20	25	0	0
Nalidixic Acid	88.5	100	100	100	100
Nitrofurantion	31.8	80	100	-	-
Piperacillin/Tazobactam	10.2	20	0	0	0
Tetracycline	88.5	100	100	100	100
Vancomycin	-	-	-	0	0